merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Eli Lilly emphasizes the safety and FDA approval of its vials compared to less regulated compounded drugs.</answer>
<question_number>2</question_number>
<answer>LillyDirect directly connects patients with providers and dispenses medication, replicating the telehealth model.</answer>
<question_number>3</question_number>
<answer>Lack of rigorous safety and efficacy oversight compared to FDA-approved medications.</answer>
<question_number>4</question_number>
<answer>It aims to attract price-sensitive customers who might otherwise opt for cheaper compounded alternatives.</answer>
<question_number>5</question_number>
<answer>Lilly argues that once the shortage is addressed, the justification for compounding tirzepatide diminishes.</answer>
<question_number>6</question_number>
<answer>It highlights a potential shift towards bypassing traditional insurance and third-party payers.</answer>
<question_number>7</question_number>
<answer>Increased out-of-pocket costs for seniors might lead them to seek less expensive but potentially riskier compounded options.</answer>
<question_number>8</question_number>
<answer>By highlighting the potential risks of compounded drugs, Lilly implicitly positions its vials as a safer alternative.</answer>
<question_number>9</question_number>
<answer>Tirzepatide's listing on the FDA's drug shortage list.</answer>
<question_number>10</question_number>
<answer>Lowering prices to compete directly with compounding pharmacies.</answer>